Cerenovus announces commercial availability of Cerepak detachable coils in USA


Cerenovus has announced that the new Cerepak detachable coils are now commercially available in the USA, and that the first patient cases have been performed. Cerepak is the latest innovation to join the company’s haemorrhagic stroke portfolio.

The Cerepak detachable coils offer three shapes and multiple coil sizes, providing physicians with comprehensive options to embolise brain aneurysms—including coils shaped specifically to achieve concentric aneurysm filling and contribute large volumetric filling.

As per a company press release, Cerepak provides physicians with a state-of-the-art delivery system designed for ease of use and reliable detachment; next-generation microcatheter stability; effortless tracking through tortuous anatomy; and reduction of radiation (fluoroscopy) exposure with fluoro-saver markers.

“I am privileged to be one of the first users of the new Cerepak detachable coils,” said Osama Zaidat (Mercy Hospital, Toledo, USA), study co-principal investigator of the STERLING registry. “The advancement of greater tools in neurology may improve patient outcomes and my team looks forward to continuing the utilisation of Cerepak coils in our treatment plans.”

This latest addition to the Cerenovus portfolio will also be included in the STERLING registry, which is currently collecting real-world data on ruptured/unruptured aneurysms treated with Micrusframe and Galaxy coils, the release further details.

“The Cerepak detachable coils provide important advancements for embolising brain aneurysms and we are pleased to expand the STERLING registry to include this latest Cerenovus offering,” said Reade De Leacy (Mount Sinai Health System, New York, USA), study co-principal investigator of the STERLING registry.

“At Cerenovus, we push the boundaries of what is possible in stroke care through continuous innovation,” said Mark Dickinson, worldwide president, Cerenovus. “Our main goal is to address unmet clinical needs and improve patient outcomes, and we are proud to announce this latest addition to our haemorrhagic portfolio that furthers our commitment to changing the trajectory of stroke.”

According to the release, in support of Cerenovus’ sustainability commitments, Cerepak is the first product in the company’s US portfolio to utilise electronic instructions for use (e-IFUs). Additionally, the Cerepak mechanical detachment system reduces waste with the elimination of a disposable battery source needed in traditional electromechanical systems.


Please enter your comment!
Please enter your name here